Cargando…

mTOR Co-Targeting in Cetuximab Resistance in Head and Neck Cancers Harboring PIK3CA and RAS Mutations

BACKGROUND: Cetuximab, a monoclonal blocking antibody against the epidermal growth factor receptor EGFR, has been approved for the treatment of squamous cell carcinomas of the head and neck (HNSCC). However, only few patients display long-term responses, prompting the search for cetuximab resistance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhiyong, Martin, Daniel, Molinolo, Alfredo A., Patel, Vyomesh, Iglesias-Bartolome, Ramiro, Sol Degese, Maria, Vitale-Cross, Lynn, Chen, Qianming, Gutkind, J. Silvio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133928/ https://www.ncbi.nlm.nih.gov/pubmed/25099740 http://dx.doi.org/10.1093/jnci/dju215

Ejemplares similares

Exploiting the mTOR paradox for disease prevention
por: Iglesias-Bartolome, Ramiro, et al.
Publicado: (2012)

A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA(+) oral cancers
por: Yamaguchi, Kosuke, et al.
Publicado: (2016)

mTOR co-targeting strategies for head and neck cancer therapy
por: Wang, Zhiyong, et al.
Publicado: (2017)

The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation
por: Kim, Ju Sun, et al.
Publicado: (2017)

Longitudinal Imaging Studies of Tumor Microenvironment in Mice Treated with the mTOR Inhibitor Rapamycin
por: Saito, Keita, et al.
Publicado: (2012)

Assembly and activation of the Hippo signalome by FAT1 tumor suppressor
por: Martin, Daniel, et al.
Publicado: (2018)

Accelerated Wound Healing by mTOR Activation in Genetically Defined Mouse Models
por: Squarize, Cristiane H., et al.
Publicado: (2010)

Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions
por: Gutkind, J. Silvio, et al.
Publicado: (2021)

Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity
por: Smith, Alison E., et al.
Publicado: (2023)

Inactivation of a Gαs-PKA tumor suppressor pathway in skin stem cells initiates basal-cell carcinogenesis
por: Iglesias-Bartolome, Ramiro, et al.
Publicado: (2015)

Oncogenic Ras is downregulated by ARHI and induces autophagy by Ras/AKT/mTOR pathway in glioblastoma
por: Zhong, Chen, et al.
Publicado: (2019)

GPR41 Regulates the Proliferation of BRECs via the PIK3-AKT-mTOR Pathway
por: Meng, Zitong, et al.
Publicado: (2023)

Effects of palbociclib on oral squamous cell carcinoma and the role of PIK3CA in conferring resistance
por: Zainal, Nur Syafinaz, et al.
Publicado: (2019)

Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer
por: Wang, Zhiyong, et al.
Publicado: (2021)

Activation of WNT/β‐catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations
por: Park, Ye‐Lim, et al.
Publicado: (2018)

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
por: Pentheroudakis, George, et al.
Publicado: (2013)

The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies
por: Martin, Daniel, et al.
Publicado: (2014)

PAM (PIK3/AKT/mTOR) signaling in glia: potential contributions to brain tumors in aging
por: Duggan, Michael R., et al.
Publicado: (2021)

Expression of an active Gα(s) mutant in skeletal stem cells is sufficient and necessary for fibrous dysplasia initiation and maintenance
por: Zhao, Xuefeng, et al.
Publicado: (2018)

MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1
por: Brundage, Meghan E., et al.
Publicado: (2014)

YAP1/TAZ-TEAD transcriptional networks maintain skin homeostasis by regulating cell proliferation and limiting KLF4 activity
por: Yuan, Yao, et al.
Publicado: (2020)

Role of mTOR, Bad, and Survivin in RasGAP Fragment N-Mediated Cell Protection
por: Peltzer, Nieves, et al.
Publicado: (2013)

Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling
por: Okoye, Isobel, et al.
Publicado: (2017)

Roles of Src family kinase, Ras, and mTOR signaling in intestinal epithelial homeostasis and tumorigenesis
por: Matozaki, Takashi, et al.
Publicado: (2020)

Insights into epithelial cell senescence from transcriptome and secretome analysis of human oral keratinocytes
por: Schwartz, Rachael E., et al.
Publicado: (2021)

Tumor-biopsy stratification based on mTOR-pathway activity and functional mutations in the upstream genes PIK3CA and PTEN
por: Laes, Jean-François, et al.
Publicado: (2017)

PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibfibroipose vascular anomaly (FAVA)
por: Hori, Yumiko, et al.
Publicado: (2022)

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
por: Liu, Xiaochun, et al.
Publicado: (2016)

Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer
por: Iwamoto, Shigeyoshi, et al.
Publicado: (2018)

Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation
por: Fang, Douglas D., et al.
Publicado: (2013)

Germline Genetic Variation Modulates Tumor Progression and Metastasis in a Mouse Model of Neuroendocrine Prostate Carcinoma
por: Patel, Shashank J., et al.
Publicado: (2013)

Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities
por: Hubbard, Paul A., et al.
Publicado: (2014)

Regulation of the Ras-MAPK and PI3K-mTOR Signalling Pathways by Alternative Splicing in Cancer
por: Siegfried, Zahava, et al.
Publicado: (2013)

Translating the Role of mTOR- and RAS-Associated Signalopathies in Autism Spectrum Disorder: Models, Mechanisms and Treatment
por: Vasic, Verica, et al.
Publicado: (2021)

Oncotargeting G proteins: The Hippo in the room
por: Feng, Xiaodong, et al.
Publicado: (2014)

Association of estrogen receptor-α and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment
por: Montero Girard, Guadalupe, et al.
Publicado: (2007)

PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations
por: di Blasio, Laura, et al.
Publicado: (2018)

BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells
por: Kim, Hee Kyung, et al.
Publicado: (2016)

Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway
por: Yan, Wei, et al.
Publicado: (2021)

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cuk6ivj72clut2fb99r97btm7o